Okuvision GmbH

Rare Disease Day: When "rare" does not mean unimportant Rare diseases affect millions of people worldwide, yet many receive little attention. Retinitis Pigmentosa (RP) is one of them. In Germany alone, around 30,000 to 40,000 people live with this progressive retinal disease, which often begins in adolescence and can lead to complete blindness. What happens in RP? The first symptoms are often night blindness and difficulty adapting to darkness. The visual field gradually narrows—leading to "tunnel vision." Over time, central vision may also be affected, sometimes resulting in complete blindness. RP has no cure, but Okuvision offers a way that may help slow disease progression and preserve vision for as long as possible. Every opportunity to protect vision matters. On Rare Disease Day, we stand with the RP community and all those living with rare diseases.

Neue Studie zu Glaukombehandlung mit transkornealer Elektrostimulation📚️ Unsere Augenklinik und Poliklinik erforscht eine innovative Methode zur Behandlung des primären Offenwinkelglaukoms, auch als Grüner Star bekannt: das transkorneale Elektrostimulationsverfahren (TES). Ziel der Pilotstudie ist es zu überprüfen, ob mit dem bereits gegen andere Augenerkrankungen erfolgreich eingesetzten elektrischen Stimulationsverfahren auch dem Fortschreiten von Gesichtsfelddefekten bei Glaukompatient:innen sicher und wirksam entgegengewirkt werden kann. Bisherige Therapieoptionen des unheilbaren Grünen Stars konnten häufig eine Verschlechterung des Befundes nicht verhindern. 🔬 Bei der transkornealen Elektrostimulation (TES) handelt es sich um ein Verfahren, bei dem schwache Strompulse durch die Hornhaut und das Auge fließen. Die elektrischen Impulse regen Schutzmechanismen in den Zellen an und können die Mikrozirkulation im Auge verbessern. So können die Zellen der Netzhaut davor bewahrt werden abzusterben und das Gesichtsfeld könnte länger erhalten bleiben. 👁️ Die monozentrische Studie „Transcorneal Electrical Stimulation for the treatment of visual field defects in patients with open-angle glaucoma (TES-GPS)“ mit einem Gesamtvolumen von rund 1,1 Millionen Euro wird von der Okuvision GmbH gesponsert und zu 50 Prozent vom Bundesministerium für Bildung und Forschung (BMBF) gefördert. Sie wird in enger Zusammenarbeit mit dem Interdisziplinären Zentrum Klinische Studien (IZKS) der Universitätsmedizin Mainz durchgeführt. 🩺 Mehr Infos: https://fcld.ly/yar3udj

Okuvision will be attending the AAD Congress for the first time, and we are excited to be part of this important event in ophthalmology. From March 19-22, 2025, we will be in Düsseldorf to connect with professionals, gain new insights, and introduce our OkuStim Therapy to preserving vision in patients with Retinitis Pigmentosa. We look forward to discussing its potential, exchanging knowledge, and engaging in meaningful conversations. Visit us at booth #214 – we look forward to meeting you.

Live from Hüttenreute: Strategy, Collaboration & Shared Moments Right now, our team is gathered in Hüttenreute for our annual Okuvision team meeting. These two days are all about deep discussions, fresh ideas, and aligning on our vision for the future. But what truly makes this time special is the fantastic people behind it—bringing dedication, passion, and teamwork to everything we do. And of course, no Okuvision team meeting would be complete without our legendary hut evening! Tonight, our marketing team is challenging us with a Pub Quiz—who will claim the title of Okuvision Quiz Champion? Stay tuned! Exciting times lie ahead, and we’re preparing something truly special for this spring. We can’t reveal more just yet, but you’ll want to keep an eye on us! A big thank you to our wonderful team for their energy, ideas, and team spirit. Here’s to another year of innovation, impact, and shared success! #Okuvision #TeamSpirit

New Retina View Podcast: Patient Perspectives from RIWC 2024 The latest episode features exclusive insights from the Retina International World Congress (RIWC) in Dublin, a key event bringing together researchers, clinicians, and patient representatives. The discussion focuses on groundbreaking advances in retinal disease treatments, including new studies aimed at slowing or even halting conditions like retinitis pigmentosa. Beyond the science, the episode also explores access to clinical trials and therapies, with a strong emphasis on patient benefits. As part of the podcast, Alfred Stett, CEO of Okuvision, was interviewed and shared his perspective on the importance of truly understanding patient needs. A key takeaway for him is the need for better methods to measure therapy outcomes—especially when it comes to capturing patients' subjective experiences. He found it striking that, while regulatory authorities prioritize vision improvement, many discussions emphasized the value of stabilizing vision and slowing disease progression—key aspects not adequately measured by current clinical methods. This aligns closely with Okuvision’s approach, making the exchange especially valuable. Listen to the full discussion: https://bit.ly/4hmELnG #RetinalHealth #TESTherapy #RetinitisPigmentosa #RIWC2024

Today, we celebrate Guide Dogs – our heroes on four paws! Guide dogs are more than just companions; they are lifelines for people with visual impairments. They provide independence, trust, and unwavering support, helping their handlers lead self-determined lives. On January 29, Guide Dog Day, let’s take a moment to thank these incredible helpers and the trainers who prepare them for their vital roles. Here’s how you can show your support: - Don’t distract a guide dog while it’s wearing its harness—it’s working! - Respect their access rights, even in places where pets aren’t allowed. - Make room on sidewalks to give guide dogs and their handlers safe passage. A big thank you to all the guide dogs out there—you truly make the world a better place! #GuideDogDay #Accessibility #ThankYouGuideDogs

A New Chapter: Okuvision and Paratriathlete Anja Renner We are very happy to announce the start of an exciting collaboration with Paratriathlete Anja Renner. Diagnosed with Usher syndrome just 25 years old, Anja’s vision was reduced to just 10% due to retinitis pigmentosa (RP). However, she refused to let this define her, instead transforming her journey into one of remarkable achievement. She began eight years ago with triathlon, culminating in a strategic entry into para-sports in February 2023. Just one and a half year later, she secured a bronze medal at the 2024 Paris Paralympics - a testament to her extraordinary determination. What makes this partnership even more meaningful is that Anja uses OkuStim herself as part of her vision preservation strategy. At Okuvision, we are committed to empowering individuals with RP, helping them manage their condition and lead fulfilling lives. With innovations like OkuStim therapy, we provide the tools needed to continue pushing forward — just as Anja does in her athletic career. Together, we are excited to support Anja’s path toward Paralympic Gold in Los Angeles 2028 and witness firsthand how medical innovation can support athletes and individuals to break down barriers. This partnership is a powerful reminder of the strength of the human spirit, and we are proud to be part of Anja’s journey. Follow us to cheer on Anja as she conquers her athletic milestones, and join us in exploring how medical innovation continues to shape lives and inspire greatness! #Okuvision #AnjaRenner #OkuStim #Paralympics #BreakingBarriers #LosAngeles2028

🎉 Okuvision’s Event Calendar 2025 is here! 🌟 We are excited to share the key dates for all our upcoming events in 2025. These occasions provide an excellent opportunity to connect with our community, showcase the latest advancements in our TES therapy, and exchange insights with professionals dedicated to supporting people living with Retinitis Pigmentosa. 📅 Mark your calendars and join us at these exciting events! And here’s a little teaser: 2025 will bring exciting news at Okuvision. Stay tuned—there’s more to come, but we’re not revealing everything just yet! 👀 We look forward to meeting patients, partners, and industry experts to continue shaping the future of care for Retinitis Pigmentosa together. Let’s make 2025 a year of innovation, collaboration, and shared success! 🚀 #Okuvision #TEStherapy #InnovationInSight #MedicalTechnology

✨ „Wir Betroffenen sind für jeden Tag, an dem wir noch etwas sehen können, sehr dankbar.“ On the website of Retina Suisse, the Swiss patient association for retinal diseases, Andreas Zimmermann shares his experience with Retinitis Pigmentosa (RP) and the OkuStim therapy. Since 2019, Andreas has been using this therapy, which aims to slow the progression of RP and potentially preserve vision for a longer time. In the article, he describes how the therapy works, its application at home, and his personal impressions of its effects. 💡 Highlights from the Retina Suisse article: ✅ Andreas’ personal experiences with the OkuStim therapy ✅ Insights into how the therapy could slow the progression of RP ✅ What patients can expect from the treatment Andreas’ story underscores the importance of innovative solutions for people living with RP and the hope they can offer. 👉 Read the full article on Retina Suisse’s website: https://bit.ly/427D5JK #RetinitisPigmentosa #OkuStim #MedTech #Innovation #PatientPerspective #PreserveVision #RetinaSuisse #Okuvision

🌍 World Braille Day – A Celebration of Accessibility and Inclusion On January 4th, we celebrate World Braille Day, honoring the transformative power of Braille in empowering blind and visually impaired individuals worldwide. Invented in 1824 by Louis Braille, this tactile writing system has opened up pathways to education, employment, and independence for millions. For those with visual impairments, Braille is more than just a set of raised dots – it is a vital tool for self-determination and active participation in society. Whether it’s reading a book, navigating a building, or accessing digital devices, Braille ensures that no one is left behind in our increasingly text-based world. 💡 Did you know? There’s even a Braille version of LEGO® bricks! These tactile toys help blind children learn Braille while playing, fostering both literacy and creativity in a truly inclusive way. At Okuvision, we are committed to advancing solutions that improve the quality of life for individuals with visual impairments. On this important day, we reflect on how innovations like Braille continue to shape a more accessible and equitable future for all. Let’s work together to promote accessibility and inclusion in every aspect of life. #WorldBrailleDay #Accessibility #Inclusion #VisualImpairment #Braille